The #ASH15 wall of people marching to the poster hall just after 5pm
Orlando – it’s Monday at the annual meeting of the American Society of Hematology (ASH) annual meeting, a day I call “Manic Monday” because there are so many simultaneous sessions, you end up running around frazzled, in/out of sessions, in the hope of catching all the presentations of interest.
It’s particularly challenging if you are in a full session — you won’t be able to get back in if you leave — which results in having to make difficult choices on what to see and where to run to. Some of the myeloma thought leaders were urging colleagues to tweet sessions they couldn’t be in, so “Manic Monday” may be a good time to contribute to the collective ASH Twittersphere.
We’re starting today’s rolling post with my notes from the lymphoma New Drugs session yesterday, then we’ll be updating the blog as the day goes by, as the opportunity permits.
Subscribers can login or you can purchase access.
This year has been an unprecedented Grand Cru year for the field of multiple myeloma, with no less than four drugs approved by the FDA to date… the fourth one just this morning while writing this preview!
- Panobinostat (Farydak) in relapsed/refractory disease in combination with bortexomib plus dexamethsone after at least 2 prior therapies.
- Daratumumab (Darzalex) received accelerated approval based on phase 2 data and is human CD38-directed monoclonal antibody that is indicated for the treatment of patients who have received at least three prior lines of therapy.
- Ixazomib (Ninlaro) is the first oral proteasome inhibitor and is approved in combination with lenalidomide plus dexamethasone, in people who have received at least one prior treatment.
- Elotuzumab (Empliciti) is a monoclonal antibody against CS–1/SLAMF7 approved today in combination with lenalidomide plus dexamethasone after 1–3 lines of prior therapy.
There are also many promising new agents in development and quite a few that may well not make it to market as a result of newer, better tolerated agents coming through.
To learn more about our insights on multiple myeloma, subscribers can log in to read our latest ASH 2015 Preview.
Downtown Disney, Orlando
It’s an exciting week for cancer drug development with the AACR-NCI-EORTC molecular targets meeting in Boston (Twitter: #Targets15) and the 2015 annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD (Twitter: #SITC2015)
However, today’s news is the much anticipated release of the abstracts (apart from the late breakers and press program) for the 2015 American Society of Hematology (ASH) annual meeting (Twitter: #ASH15) that takes place in Orlando from December 5-8th. We’ll at the meeting for the blog.
There is so much great science at ASH, it’s really hard to do it justice – we’ve been known to spend most of the meeting in the poster halls…and until you see the data it’s impossible to provide detailed commentary or analysis.
However, there’s so much interest in the abstracts that for the benefit of our subs, I’ve highlighted several that caught my attention in what is a fast, real-time, top-line review while at SITC this morning.
This initial review covers two hot topics in cancer immunotherapy – CAR T cells and Checkpoint inhibitors.
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.